Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
This study was prematurely discontinued after approximately 5 years. The decision to prematurely discontinue the study was not taken due to safety-related concerns, rather due to a decision to focus the development of siponimod in MS on a different population.
Age
18–56
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients completed the core study BAF312A2201
Written informed consent provided before any assessment of the extension study
Female patients at risk of becoming pregnant must have a negative pregnancy test and use simultaneously two forms of effective contraception
You may not be if
Newly diagnosed systemic disease other than MS (which may require immunosuppressive treatment)
Malignancies, diabetes, significant cardiovascular and pulmonary diseases and conditions
Active infections
Clareo Health | Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
